Prometheus Biosciences, Inc. (RXDX)
|Net Income (ttm)||-37,138|
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, filed on Friday with the SEC to raise up to $125 million in an initial public of...
Prometheus Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.
Prometheus Biosciences is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). We leverage our proprietary precision medicine platform, Prometheus360™, which includes one of the world’s largest gastrointestinal (GI) bioinformatics databases, to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, we are developing ... [Read more...]
|IPO Date |
Mark C. McKenna
|Stock Exchange |
|Ticker Symbol |
In 2020, RXDX's revenue was $1.23 million, an increase of 9.93% compared to the previous year's $1.12 million. Losses were -$37.14 million, 24.9% more than in 2019.